HUE049501T2 - Nitazoxanidot tartalmazó szabályozott felszabadulású gyógyszerkészítmény - Google Patents
Nitazoxanidot tartalmazó szabályozott felszabadulású gyógyszerkészítményInfo
- Publication number
- HUE049501T2 HUE049501T2 HUE10741758A HUE10741758A HUE049501T2 HU E049501 T2 HUE049501 T2 HU E049501T2 HU E10741758 A HUE10741758 A HU E10741758A HU E10741758 A HUE10741758 A HU E10741758A HU E049501 T2 HUE049501 T2 HU E049501T2
- Authority
- HU
- Hungary
- Prior art keywords
- controlled release
- release formulation
- formulation containing
- containing nitazoxanide
- nitazoxanide
- Prior art date
Links
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960002480 nitazoxanide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20228509P | 2009-02-13 | 2009-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049501T2 true HUE049501T2 (hu) | 2020-09-28 |
Family
ID=42560126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10741758A HUE049501T2 (hu) | 2009-02-13 | 2010-02-12 | Nitazoxanidot tartalmazó szabályozott felszabadulású gyógyszerkészítmény |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8524278B2 (enExample) |
| EP (1) | EP2395840B1 (enExample) |
| JP (3) | JP5726766B2 (enExample) |
| KR (1) | KR101697800B1 (enExample) |
| CN (2) | CN107260695A (enExample) |
| AU (3) | AU2010213678B2 (enExample) |
| BR (1) | BRPI1007945C8 (enExample) |
| CA (1) | CA2752233C (enExample) |
| CO (1) | CO6501159A2 (enExample) |
| CY (1) | CY1123162T1 (enExample) |
| DK (1) | DK2395840T3 (enExample) |
| EA (1) | EA029018B1 (enExample) |
| ES (1) | ES2797493T3 (enExample) |
| HR (1) | HRP20201055T1 (enExample) |
| HU (1) | HUE049501T2 (enExample) |
| IL (1) | IL214624A0 (enExample) |
| LT (1) | LT2395840T (enExample) |
| MX (2) | MX381895B (enExample) |
| PL (1) | PL2395840T3 (enExample) |
| PT (1) | PT2395840T (enExample) |
| SI (1) | SI2395840T1 (enExample) |
| UA (1) | UA107564C2 (enExample) |
| WO (1) | WO2010093854A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008008723A (es) * | 2006-01-09 | 2008-09-26 | Romark Lab Lc | Tratamiento de la hepatitis viral. |
| MX381895B (es) | 2009-02-13 | 2025-03-13 | Romark Laboratories Lc | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. |
| US9498441B2 (en) | 2012-01-27 | 2016-11-22 | Siegfried Rhein S.A. De C.V. | Nitazoxadine composition and process to prepare same |
| US20150017242A1 (en) * | 2012-02-20 | 2015-01-15 | Lupin Limited | Bilayer Tablet of Dronedarone |
| KR101639692B1 (ko) * | 2013-12-13 | 2016-07-14 | 제일약품주식회사 | 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물 |
| JP6633092B2 (ja) | 2014-11-11 | 2020-01-22 | ロマーク ラボラトリーズ，リミティド カンパニー | チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法 |
| HK1250945A1 (zh) | 2016-03-31 | 2019-01-18 | 罗马克实验室有限公司 | 用於治疗病毒性感染的噻唑化物化合物 |
| IL262186B2 (en) * | 2016-04-11 | 2023-10-01 | Genfit | Synergistic combinations of nitazoxanide (ntz) compounds and statins |
| US10905680B2 (en) * | 2016-04-11 | 2021-02-02 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| AU2018231044B2 (en) * | 2017-03-08 | 2023-04-06 | Cinrx Pharma, Llc | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol |
| SG11201907673YA (en) * | 2017-03-13 | 2019-09-27 | Genfit | Pharmaceutical compositions for combination therapy |
| US11173149B2 (en) | 2017-04-18 | 2021-11-16 | Romark Laboratories L.C. | Inhibition of protein disulfide-isomerase A3 |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| WO2018230713A1 (ja) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CN108524460B (zh) * | 2018-05-14 | 2021-01-01 | 佛山市南海东方澳龙制药有限公司 | 烯啶虫胺双层片 |
| WO2019241376A1 (en) | 2018-06-14 | 2019-12-19 | The Trustees Of Columbia University In The City Of New York | Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof |
| CN110025621A (zh) * | 2019-03-13 | 2019-07-19 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 替唑尼特和硝唑尼特在制备抗炎药物中的应用 |
| CN111012788B (zh) * | 2019-12-12 | 2021-01-15 | 武汉职业技术学院 | 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用 |
| US20230040902A1 (en) * | 2019-12-19 | 2023-02-09 | Celltrion Inc. | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof |
| JP2023537237A (ja) | 2020-07-20 | 2023-08-31 | ロマーク ラボラトリーズ，リミティド カンパニー | チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩 |
| IL300801A (en) | 2020-08-24 | 2023-04-01 | Romark Laboratories Lc | Use of thiazolides against the corona virus |
| WO2022130406A1 (en) * | 2020-12-15 | 2022-06-23 | Cipla Limited | Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease |
| US20240417381A1 (en) | 2021-10-05 | 2024-12-19 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated | An improved process for the preparation of nitazoxanide and intermediates thereof |
| CN114259492A (zh) * | 2021-12-21 | 2022-04-01 | 中以海德人工智能药物研发股份有限公司 | 硝唑尼特在治疗乙肝中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| JPH06316517A (ja) * | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| US5578621A (en) | 1994-09-08 | 1996-11-26 | Romark Lab Lc | Benzamide derivatives |
| US5387598A (en) | 1994-04-13 | 1995-02-07 | Rossignol; Jean-Francois | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| SI20149B (en) * | 1997-05-07 | 2001-08-31 | Romark Lab Lc | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5948440A (en) | 1997-12-17 | 1999-09-07 | Ranbaxy Laboratories Limited | Modified release matrix formulation of cefaclor and cephalexin |
| IL142896A0 (en) | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
| GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
| DE10031043A1 (de) | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
| JP4637338B2 (ja) * | 2000-09-22 | 2011-02-23 | 大塚製薬株式会社 | シロスタゾール有核錠 |
| CA2426666A1 (en) | 2000-09-29 | 2002-04-04 | Solvay Pharmaceuticals B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| US7074417B2 (en) | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| MXPA04002973A (es) | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Formas de dosis de liberacion modificada. |
| KR20040044992A (ko) | 2001-09-28 | 2004-05-31 | 썬 파마슈티컬 인더스트리스 리미티드 | 당뇨병 치료용 투여형태 |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| AR045330A1 (es) | 2003-08-07 | 2005-10-26 | Sb Pharmco Inc | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla |
| GB0319874D0 (en) * | 2003-08-22 | 2003-09-24 | Glaxo Group Ltd | Novel formulation |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| WO2006070406A1 (en) * | 2004-12-29 | 2006-07-06 | J.B. Chemicals & Pharmaceuticals Ltd | Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof |
| AU2006235490A1 (en) | 2005-04-12 | 2006-10-19 | Romark Laboratories, L.C. | Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| MX2008008723A (es) * | 2006-01-09 | 2008-09-26 | Romark Lab Lc | Tratamiento de la hepatitis viral. |
| JP2006335771A (ja) * | 2006-09-22 | 2006-12-14 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
| US20080299188A1 (en) * | 2007-05-14 | 2008-12-04 | Pfizer Inc. | Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug |
| US20080286344A1 (en) * | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| EP2178852B9 (en) | 2007-08-03 | 2016-06-22 | Romark Laboratories, L.C. | Alkylsulfonyl-substituted thiazolide compounds |
| MX381895B (es) * | 2009-02-13 | 2025-03-13 | Romark Laboratories Lc | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. |
-
2010
- 2010-02-12 MX MX2017006915A patent/MX381895B/es unknown
- 2010-02-12 LT LTEP10741758.6T patent/LT2395840T/lt unknown
- 2010-02-12 BR BRPI1007945A patent/BRPI1007945C8/pt not_active IP Right Cessation
- 2010-02-12 SI SI201032014T patent/SI2395840T1/sl unknown
- 2010-02-12 DK DK10741758.6T patent/DK2395840T3/da active
- 2010-02-12 HU HUE10741758A patent/HUE049501T2/hu unknown
- 2010-02-12 EP EP10741758.6A patent/EP2395840B1/en active Active
- 2010-02-12 KR KR1020117020973A patent/KR101697800B1/ko not_active Expired - Fee Related
- 2010-02-12 HR HRP20201055TT patent/HRP20201055T1/hr unknown
- 2010-02-12 JP JP2011550246A patent/JP5726766B2/ja active Active
- 2010-02-12 WO PCT/US2010/024000 patent/WO2010093854A1/en not_active Ceased
- 2010-02-12 AU AU2010213678A patent/AU2010213678B2/en not_active Ceased
- 2010-02-12 US US12/656,704 patent/US8524278B2/en not_active Expired - Fee Related
- 2010-02-12 PT PT107417586T patent/PT2395840T/pt unknown
- 2010-02-12 MX MX2011008530A patent/MX348282B/es active IP Right Grant
- 2010-02-12 ES ES10741758T patent/ES2797493T3/es active Active
- 2010-02-12 CN CN201710263825.6A patent/CN107260695A/zh active Pending
- 2010-02-12 CA CA2752233A patent/CA2752233C/en not_active Expired - Fee Related
- 2010-02-12 EA EA201190127A patent/EA029018B1/ru not_active IP Right Cessation
- 2010-02-12 CN CN2010800164251A patent/CN102395276A/zh active Pending
- 2010-02-12 PL PL10741758T patent/PL2395840T3/pl unknown
- 2010-12-02 UA UAA201110567A patent/UA107564C2/uk unknown
-
2011
- 2011-08-11 IL IL214624A patent/IL214624A0/en active IP Right Grant
- 2011-09-07 CO CO11115308A patent/CO6501159A2/es not_active Application Discontinuation
-
2013
- 2013-07-30 US US13/954,184 patent/US9351937B2/en not_active Expired - Fee Related
-
2015
- 2015-04-01 JP JP2015075264A patent/JP6117845B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-16 AU AU2016200971A patent/AU2016200971B2/en not_active Ceased
- 2016-04-29 US US15/141,921 patent/US9827227B2/en not_active Expired - Fee Related
- 2016-12-09 JP JP2016239374A patent/JP6491174B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-11 AU AU2017203148A patent/AU2017203148B2/en not_active Ceased
- 2017-11-16 US US15/814,850 patent/US10383855B2/en active Active
-
2019
- 2019-07-02 US US16/460,161 patent/US11426388B2/en active Active
-
2020
- 2020-07-07 CY CY20201100626T patent/CY1123162T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE518527T1 (de) | Rasagilinformulierung mit verzögerter freisetzung | |
| DK2433475T3 (da) | Nanostrukturerede materialer til batterianvendelser | |
| ZA201204266B (en) | Antibody formulation | |
| IL214956A0 (en) | Antibody formulation | |
| IL217153A0 (en) | Controlled release formulations | |
| ZA201203242B (en) | Antibody formulation | |
| PL2475352T3 (pl) | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji | |
| DK2225988T3 (da) | Dispenserhus | |
| DK2395840T3 (da) | Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse | |
| BRPI1009465A2 (pt) | Formulação | |
| AP2011005989A0 (en) | A novel formulation of diclofenac. | |
| DK3320979T3 (da) | Dispenser | |
| GB2499165B (en) | Absorbent article configured for controlled deformation | |
| PL2554168T3 (pl) | Kompozycja farmaceutyczna do kontrolowanego uwalniania | |
| GB0907003D0 (en) | Formulation | |
| IL214251A0 (en) | Isoxazole derivatives | |
| ZA201200568B (en) | Fentanyl-containing adhesive preparation for external use | |
| BRPI1012729A2 (pt) | dispensador | |
| IT1397007B1 (it) | Dispenser | |
| DK2463458T3 (da) | Rigelanordning til et låselegeme | |
| PH12012501255A1 (en) | Sustained release formulation | |
| HUE042857T2 (hu) | Gyors hatóanyag-leadású készítmények | |
| NO20092178L (no) | Emballasje for sma objekter | |
| ES1070615Y (es) | Envase flexible para monodosis | |
| GB0911213D0 (en) | Formulation |